JP2023550591A5 - - Google Patents

Info

Publication number
JP2023550591A5
JP2023550591A5 JP2023526609A JP2023526609A JP2023550591A5 JP 2023550591 A5 JP2023550591 A5 JP 2023550591A5 JP 2023526609 A JP2023526609 A JP 2023526609A JP 2023526609 A JP2023526609 A JP 2023526609A JP 2023550591 A5 JP2023550591 A5 JP 2023550591A5
Authority
JP
Japan
Prior art keywords
alkyl
group
membered
cycloalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023526609A
Other languages
English (en)
Japanese (ja)
Other versions
JP7805363B2 (ja
JP2023550591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/080151 external-priority patent/WO2022090481A1/en
Publication of JP2023550591A publication Critical patent/JP2023550591A/ja
Publication of JP2023550591A5 publication Critical patent/JP2023550591A5/ja
Application granted granted Critical
Publication of JP7805363B2 publication Critical patent/JP7805363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023526609A 2020-11-02 2021-10-29 EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体 Active JP7805363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20205297.3 2020-11-02
EP20205297 2020-11-02
PCT/EP2021/080151 WO2022090481A1 (en) 2020-11-02 2021-10-29 Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors

Publications (3)

Publication Number Publication Date
JP2023550591A JP2023550591A (ja) 2023-12-04
JP2023550591A5 true JP2023550591A5 (cg-RX-API-DMAC7.html) 2024-11-05
JP7805363B2 JP7805363B2 (ja) 2026-01-23

Family

ID=73059474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526609A Active JP7805363B2 (ja) 2020-11-02 2021-10-29 EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体

Country Status (7)

Country Link
US (2) US12064421B2 (cg-RX-API-DMAC7.html)
EP (1) EP4237423B1 (cg-RX-API-DMAC7.html)
JP (1) JP7805363B2 (cg-RX-API-DMAC7.html)
CN (1) CN116507627B (cg-RX-API-DMAC7.html)
AR (1) AR123977A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233637A (cg-RX-API-DMAC7.html)
WO (1) WO2022090481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
KR20240133663A (ko) * 2023-02-28 2024-09-04 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
KR20240152239A (ko) * 2023-04-11 2024-10-21 보로노이 주식회사 피라졸로피리딘 유도체 화합물 및 이의 용도
CN117069746B (zh) * 2023-08-17 2025-10-21 苏州共康医药科技有限公司 取代的吡唑并吡啶类化合物作为4代egfr抑制剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477505A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2003226149A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
EP1636224B1 (en) 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
US7557211B2 (en) 2004-11-12 2009-07-07 Bristol-Myers Squibb Company 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
EP2114916A2 (en) 2007-02-02 2009-11-11 NeuroSearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN103059014B (zh) 2011-10-21 2016-05-18 北京韩美药品有限公司 新型杂芳基氨基衍生物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
US20150152083A1 (en) 2012-06-06 2015-06-04 Irm Llc, A Delaware Limited Liability Company Compounds and Compositions for Modulating EGFR Activity
KR20150028999A (ko) * 2012-06-27 2015-03-17 에프. 호프만-라 로슈 아게 5-아자인다졸 화합물 및 이의 사용 방법
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
WO2015025026A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
CN104418858B (zh) 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
EP3082810B1 (en) 2013-12-18 2018-09-26 Merck Sharp & Dohme Corp. Erk inhibitors
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
CA2943231C (en) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
IL291000B2 (en) 2014-03-20 2024-04-01 Capella Therapeutics Inc Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
EP3912979B1 (en) 2015-06-03 2026-03-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
ES2745284T3 (es) 2015-09-11 2020-02-28 Boehringer Ingelheim Int Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
WO2017120429A1 (en) * 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN110139862B (zh) 2016-11-03 2024-01-16 百时美施贵宝公司 可用作romk通道抑制剂的经取代的二环杂环衍生物
BR112019022074A2 (pt) 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
WO2019105886A1 (en) 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
JP7313364B2 (ja) * 2018-02-21 2023-07-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors

Similar Documents

Publication Publication Date Title
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2024508755A5 (cg-RX-API-DMAC7.html)
JOP20220271A1 (ar) مركبات دايازينو بيريميدين كمثبطات لـ her2
JP2016501189A5 (cg-RX-API-DMAC7.html)
JP2012532136A5 (cg-RX-API-DMAC7.html)
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
EP3277276B1 (en) Methods of administering glutaminase inhibitors
JP2013502431A5 (cg-RX-API-DMAC7.html)
JP2017511360A5 (cg-RX-API-DMAC7.html)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2005533748A5 (cg-RX-API-DMAC7.html)
AU2025204720A1 (en) Methods for treating testicular and ovarian adrenal rest tumors
JP2019526596A5 (cg-RX-API-DMAC7.html)
JP2014503567A5 (cg-RX-API-DMAC7.html)
JP2017519781A5 (cg-RX-API-DMAC7.html)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2014512364A5 (cg-RX-API-DMAC7.html)
JP2020527173A5 (cg-RX-API-DMAC7.html)
HRP20220351T1 (hr) 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
BR112013021941B1 (pt) Agente terapêutico para tumor
JP2020533352A5 (cg-RX-API-DMAC7.html)
JP2017502940A5 (cg-RX-API-DMAC7.html)
SI3166925T1 (en) Isoindoline derivatives for use in treating a viral infection
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2014512355A5 (cg-RX-API-DMAC7.html)